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1. Introduction 
Estrogen plays a key regulatory role in a number of biological processes and, in addition to 
its classic function as a sex hormone, it has been linked to neurodegenerative diseases, 
including Alzheimer's disease (AD) (Wickelgren, 1997; Brann et al., 2007; Zhang et al., 2007). 
However, long-term compliance with estrogen therapy is often estimated to be no more 
than 15%–40%, due to its undesirable side-effects, such as an increased risk of developing 
breast and uterine cancer (Warren, 2004). Therefore, the body of recent research has focused 
on finding neuro-selective estrogen receptor agonists (Zhao et al., 2005) that mimic the 
beneficial effects of estrogen in the brain but which also exert negligible adverse effects on 
non-neural estrogen-responsive tissues. For instance, propylpyrazole triol and 
diarylpropionitrile – each of which exhibits relative specificity for the estrogen receptors 
ERǂ and ERǃ respectively – have been proven to differentially regulate AD-like changes in 
female AD model mice (Carroll and Pike, 2008). Additionally, some phytoestrogens with 
fewer side-effects and potential neuroprotective effects have been developed for use in 
alternative treatment strategies (Zhao et al., 2002; Bang et al., 2004).  
Liquiritigenin (7, 4’-dihydroxyflavanone) is a flavonoid extracted from the radix of 
Glycyrrhiza, an herbal that is frequently used to treat injury or swelling, or for detoxification 
in traditional Oriental medicine. Liquiritigenin is also one of the major active compounds of 
MF101 (Kupfer et al., 2008), an herbal extract currently used in clinical trials for the 
treatment of hot flushes and night-sweats in post-menopausal women. Our interest in 
liquiritigenin is based upon the following observations. First, liquiritigenin is shown to be a 
selective agonist of estrogen receptor-ǃ (ERǃ) (Mersereau et al., 2008). ERǃ is expressed in 
the brain centre related to learning and memory, but it is unlikely to be related to sex 
(Shughrue et al., 1997; Gustafsson et al., 2003). Second, studies have already proven that 
liquiritigenin exerts cytoprotective effects in vitro and in vivo (Kim et al., 2004; Kim et al., 
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2006; Kim et al., 2008); in particular, we have previously observed that liquiritigenin inhibits 
amyloid ǃ-peptide-induced neurotoxicity, not only in hippocampal neurons (Liu et al., 
2009), but also in rats (Liu et al. 2010a). Third, we have found that liquiritigenin does not 
induce the proliferation of MCF-7 or T47D breast cancer cells (unpublished observations), 
which is consistent with the results of other studies (Gustafsson et al., 2003). Finally, 
pharmacokinetics data has demonstrated that liquiritigenin is absorbed well by the intestine 
amongst rats, with an in vitro blood-brain barrier penetration rate of (29.7±6.8)% within 90 
min, similar to that of chloramphenicol (34.0±4.9)%, a known blood-brain barrier and highly 
penetrative drug (Kupfer et al., 2008; Lu et al., 2008; Kang et al., 2009). Taken together, these 
observations suggest that liquiritigenin may be a potentially effective therapy for AD.  
2. Methods 
2.1 Animals 
Male and female 10-month-old transgenic 2576 (Tg2576) mice expressing the human 695 aa 
isoform of amyloid protein precursor (APP) and containing the mutation (K670N and 
M671L) were purchased from the Chinese Academy of Medical Sciences. Tg2576 mice and 
age- and strain-matched wild type (WT) mice (C57/BL6J) were housed with free access to 
standard food and water at a room temperature of 21±2°C, relative humidity of 45±15%, and 
12 h light/dark cycles. All experimental manipulations and data analysis in this study were 
conducted in a blinded fashion. 
All animal experiments were conducted in accordance with NIH guidelines under a 
protocol adhering to the guidelines of the Chinese Society of Laboratory Animal Sciences. 
2.2 Experimental design 
Liquiritigenin was synthesised at the Beijing Institute of Radiation Medicine (Beijing, China) 
and it was shown to be >95% pure by HPLC. Tg2576 mice – a widely used AD model (Spires 
et al., 2005; Howlett et al., 2009) – were randomly assigned to one of four liquiritigenin 
treatment groups (n= 5 male and 5 female/group): 30 mg/kg/d, 10 mg/kg/d, 3 mg/kg/d 
and 0 mg/kg/d (control vehicle treatment). Each treatment group received liquiritigenin 
continuously for 90 d (i.g.); the WT and vehicle-treated Tg2576 mice were treated with an 
identical volume (20 ml/kg/d) of vehicle (0.1% sodium carboxymethyl cellulose).  
Animal behaviour was assessed from the 91st day from the beginning of treatment, with the 
tests carried out sequentially in accordance with the experimental schedule shown in Fig. 1.  
 
 
Fig. 1. Experimental schedule of behaviour tests. 
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2.3 Morris water maze test 
A circular water tank (100-cm diameter, 40 cm tall, purchased from Chinese Academy of 
Medical Sciences) was divided into four equally spaced quadrants. A transparent platform 
was set at the east quadrant of the tank, 20 cm from the wall and 1 cm below the surface of 
the water.  
Reference memory task: The task was conducted twice a day for 4 consecutive days. In each 
trial, the mouse was placed in the water at one of three starting positions (which were 
spaced equally around the rim of the tank), with the sequence of the positions selected at 
random. The mouse was allowed to swim until it found the platform or until 90 s had 
elapsed. In this last case, the trial was terminated and the animal was put on the platform 
for 30 s. The latency of escape onto the platform was recorded using Morris system software 
(Chinese Academy of Medical Sciences). 
Probe task: On day 95, the platform was removed from the pool and the animals underwent 
a 90 s spatial probe trial. The time taken to reach the place where the platform had been 
located during training and the length of time spent in that quadrant was recorded. 
2.4 Two-way shuttle avoidance task 
The two-way shuttle avoidance box, placed in a dimly-lit, ventilated, sound-attenuated 
cupboard, is a rectangular chamber (44×28×23 cm, purchased from Chinese Academy of 
Medical Sciences) used to condition animals with a shock stimulus. During the conditioning 
stimulus (5 s of singing on a loudspeaker located on the ceiling), the animals had to move to 
the other side of the shuttle box in order to avoid a 2 s electrical shock of the foot 
(unconditioned stimulus). Between trials, the animals were able to move with impunity for 40 
s. Every mouse was subjected to 10 trials per day for 4 consecutive days, and the time spent in 
avoidance (shuttling to the other part of the apparatus while the tone was on so as to avoid the 
shock), the frequency of the shock, and the length of time in shock were recorded.  
2.5 Brain slice and homogenate preparation 
After the above behavioural assessment was completed, all the mice were anesthetised with 
pentobarbital (50 mg·kg-1, i.p.), transcardially perfused with cold physiological saline, and 
killed by decapitation. Each cerebrum was divided into 3 parts. One part of the cerebral 
hemispheres was collected immediately and immersion-fixed in 4% paraformaldehyde for 
paraffin sections. Half of the remaining cerebral hemisphere were weighed and immediately 
used to make a 10% homogenate with saline by centrifugation at 3500 rpm for 10 min at 4 
°C, and which were stored in -80°C until use. The remaining half of the hemispheres were 
lysed with 4°Ccell lysis buffer (Beyotime, P0013, China) for protein extraction – as described 
by the manufacturer – and stored at -80°C.  
2.6 Detection of acetylcholinesterase and choline acetyltransferase activity 
Acetylcholinesterase (AchE) and choline acetyltransferase (Chat) activity was detected in the 
10% brain homogenate using commercial kits (Nanjing Jiancheng Bioengineering Institute, 
China) according to the manufacturer’s instructions. The absorbencies were determined 
with a spectrophotometer (DU-640, Beckman, USA). 
2.7 Aβ/A4 immunostaining  
Fixed hemibrains were blocked, sectioned (4 μm) exhaustively in the horizontal plane, 
and then processed for immunohistochemistry using a standard avidin-biotin peroxidase 
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complex protocol. Briefly, every section was immunostained using an antibody directed 
against Aǃ/A4 (Santa Cruz, sc-28365, 1:100 dilution) at 4°C overnight, followed by signal 
development using an avidin-biotin peroxidase complex immunohistochemistry kit 
(Zhongshan Goldenbridge Bio Co., Ltd., PV-9002, China), diaminobenzidine for colour 
substrate reactions, and haematoxylin for counterstaining. The level of Aǃ/A4 
immunoreactivity in the hippocampus CA1, subiculum, amygdala, and cortex was 
quantified. In the hippocampus CA1, three adjacent but non-overlapping fields were 
captured for load analysis. In the subiculum and amygdala, we similarly captured two 
fields per section; in the cortex, six adjacent, non-overlapping fields were captured. The 
fields of immunolabelled sections were imaged and digitised using a video-capture 
system (a CCD camera coupled to an Olympus Optical Microscope, Tokyo, Japan) and the 
density of the images was quantified with Motic Images Advanced 3.2 software (on the 
internet at http://www.microscopeworld.com), using stereological approaches. All these 
assessments were performed by experimenters who were blinded to the genotypes of each 
brain section.  
2.8 Determination of Aβ/A4 protein levels by Western blotting 
Western blotting was performed to further validate the results of immunostaining. Briefly, 
protein concentrations were measured using a bicinchoninic acid protein determination 
kit (Walterson, H10020, China), and 40 μg protein per lane was analysed. SDS-PAGE and 
Western blotting were performed according to standard protocols (Zhang et al., 2007). The 
same Aǃ/A4 antibody was used (1:500 dilution) and ǃ-tubulin (Walterson, China, 1:1000 
dilution) served as an internal control. A goat anti-mouse IgG-HRP secondary antibody 
was used (Zhongshan Goldenbridge Bio Co., Ltd., China, 1:5000 dilution). Levels of 
Aǃ/A4 were expressed as a ratio of Aǃ/A4 to ǃ-tubulin signal, which was determined 
with Scion Image software (Scion Image for Windows ǃ 4.02, on the internet at http:// 
www.scioncorp.com). 
2.9 Nissl staining for neurons 
Nissl staining was directly used for routine histology with cresyl violet (C 1791, Sigma, 
USA). Briefly, sections were dipped into an aqueous solution of cresyl violet (0.5%) at 37°C 
for 20 min and then washed with distilled water followed by 70% ethanol. The density of 
CA1 and cortex pyramidal neurons was quantified with Motic Images Advanced 3.2 
software using stereological approaches. 
2.10 Detection of astrogliosis by immunostaining 
Polyclonal rabbit anti-mouse glial fibrillary acidic protein (GFAP, Zhongshan, ZA-0117, 
China, 1:100 dilution) antibody was used for the immunostaining of astrocytes. The staining 
and analysis were conducted as described in Aǃ/A4 immunostaining; the level of GFAP 
immunoreactivity was quantified in the hippocampus CA1 only.  
2.11 Determination of Notch-2 expression by Western blotting 
SDS-PAGE and Western blotting were performed according to standard protocols (Zhang et 
al., 2007) with an antibody against Notch-2 intracellular domains (Notch-2 IC, ab-52302, 
Abcam, UK, 1:300 dilution); 100 μg protein per lane was analysed. Otherwise, the procedure 
and reagents used were as described with Western blotting.  
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2.12 Aβ peptide oligomerisation assay in vitro 
Soluble Aǃ1-42 (100 μM) was dissolved in saline with 0, 0.02, 0.2 or 2 μM liquiritigenin 
(doses chosen based upon our preliminary tests) or 100 μM melatonin (positive control) and 
incubated at 37°C for 7 d so as to induce fibril formation. We then added 10 μl of this, 
conditioned Aǃ1-42 to 990 μl 5 μM thioflavin-T (Th-T, Sigma, USA) dissolved in 50 mM 
glycine-NaOH (pH 8.5), and measured the fluorescent intensity of the liquid with a 
fluorescence spectrophotometer (excitation=435 nm, emission=485 nm). 
Primary cerebrum neuron cells were obtained from newborn (<12 h postnatal) C57 mice 
following methods already reported (Zhao et al., 2002). These neurons were seeded into 
poly-D-lysine-coated 96-well plates at a density of 1.0×105 cells per well. To evaluate the 
toxicity of these, conditioned Aǃ1-42, 7 day-old neuron cells were treated with the 
conditioned Aǃ1-42 for 72 h. Cell viability was measured with a 3-[4,5-dimethyl-thiazolyl]-
2,5- diphenyl-2- tetrazolium bromide (Sigma, USA) assay (Zhao et al., 2002), and cellular 
membrane penetrability was evaluated by measuring the amount of cytoplasmic lactate 
dehydrogenase released into the medium (Zhao et al., 2002) with a commercial kit (Biosino 
Bio-technology and Science Inc., Beijing, China). 
2.13 Investigation of the mechanism underlying Notch-2 inhibition in vitro 
We used the specific ER antagonist ICI 182 780 (Faslodex) to ascertain whether there was an 
inhibitory effect of liquiritigenin on Notch-2 involved ER. Primary cerebrum stem/precursor 
cells were obtained from newborn (<12 h postnatal) C57 mice using reported methods (Ray 
and Gage, 2006); these were grown for 7 days and seeded into 6-well plates at a density of 
1.5×106 per well. The cells were treated with either vehicle ICI 182 780 (200 nM) alone or 
liquiritigenin alone (0.02, 0.2 or 2 μM), or else 2 μM liquiritigenin plus 200 nM ICI 182 780. ICI 
182 780 was added 1 h prior to the liquiritigenin treatment, and liquiritigenin was incubated 
with ICI 182 780 for 5 d. Throughout the treatment, the medium was changed every other day; 
each change of media contained the appropriate drug concentrations. 
Reverse transcriptase-polymerase chain reaction analysis and Western blotting were 
performed in order to determine changes of Notch-2 mRNA (GenBank accession no. 
NM_024358) and protein expression. Total RNA was extracted and reverse-transcribed to 
yield cDNA with commercial kits, as indicated by the manufacturer (Promega, A3500, USA). 
Polymerase chain reaction was performed using Notch-2 specific primers (forward: 5’-GCA 
TCC TGG TCA TCG TGGT-3’, reverse: 5’- GAG CCT ATT ATC TCC TGT TCC TG-3’). The 
predicted size of the amplified product was 229 bp. As an internal control, specific primers 
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (forward: 5’-CAT GAC CAG 
AGT CCA TGC CAT CACT-3’, reverse: 5’-TGA GGT CCA CCA CCC TGT TGC TGTA-3’) 
were used. Amplification was carried out for 40 cycles: 30 s at 94°C, 30 s at 59°C and 30 s at 
72°C in a thermal cycler (Gene Amp 2400, USA). The PCR products were visualised after 1% 
agarose gel electrophoresis.  
For Western blotting, the procedures and reagents used were similar to those described 
above, with an antibody against the Notch-2 intracellular domains (Notch-2 IC, ab-52302, 
Abcam, UK, 1:300 dilution), and 100 μg protein per lane was analysed. Otherwise, the 
procedures and reagents used were as already described. 
2.14 Data analysis  
All data was expressed as mean ± SEM. Assays in vitro were repeated in at least three 
independent experiments, each of which was performed in triplicate. Behavioural results 
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were analysed with a two-way ANOVA followed by Dunnett’s test; other raw data was 
compared among groups by one-way ANOVA followed by Dunnett’s test. P<0.05 was 
assumed so as to indicate statistical significance. 
3. Results 
3.1 Liquiritigenin treatment rescued behavioural impairment in the Morris water maze 
test 
Changes of escape latency in the reference memory task are shown in Fig. 2(A). The escape 
latency of mice in every group decreased gradually with increased training time, but the 
vehicle-treated Tg2576 mice exhibited significantly prolonged escape latency from day 2 to 
day 4, compared with the WT mice. Compared with the vehicle-treated Tg2576 mice, the 
liquiritigenin-treated mice required less time to reach the platform. A 90-s spatial probe trial 
was carried out after the 8th training trial. As shown in Fig. 2(B), the time required to reach 
the platform for the WT mice was 11.55±2.78 s. The vehicle-treated Tg2576 mice required a 
considerably longer time (23.65±4.84 s, P<0.05 vs. control), while the liquiritigenin-treated 
mice (10 and 30 mg/kg/d) performed better than the vehicle-treated mice (10 mg/kg/d: 
17.43±3.08 s, 30 mg/kg/d: 16.76±4.02 s, P<0.05). The vehicle-treated Tg2576 mice (16.8±2.1 s) 
also showed a significant decrease in the length of time spent in the quadrant where the 
platform had been located during training as compared to the WT mice (23.7±2.6 s). Only 
the highest dose of liquiritigenin treatment increased this parameter (20.8±2.7 s), as shown 
in Fig. 2(C). 
3.2 Liquiritigenin-treated mice perform better in the shuttle box task 
The results of the shuttle box test are shown in Fig. 2(E), (F) and (G). Compared with the WT 
mice, the vehicle-treated Tg2576 mice were shocked more times and for longer periods, and 
their initiative escaping time was significantly decreased. Compared with the vehicle-
treated Tg2576 mice (shocks: 6.7±1.3, shock time: 9.9±1.8 s, escaping time: 7.9±1.2 s), the 
liquiritigenin-treated mice (10 and 30 mg/kg/d) were shocked fewer times (10 mg/kg/d: 
3.7±0.6, 30 mg/kg/d: 2.3±0.4, P<0.05 ) and spent less time being shocked (10 mg/kg/d: 
4.6±0.8 s, 30 mg/kg/d: 3.0±0.5 s, P<0.05); their escaping time also increased (10 mg/kg/d: 
16.6±1.8 s, 30 mg/kg/d: 16.9±2.2 s, P<0.05). The performance of mice treated with a lower 
dose of liquiritigenin (3 mg/kg/d) was similar to that of the vehicle-treated mice.  
3.3 Changes in AchE and Chat activities upon liquiritigenin treatment 
The results of AchE and Chat activity determination are shown in Table 1. The activities of 
AchE and Chat in the vehicle-treated Tg2576 mice were set as 100% and used as the 
baseline. The results in Table 1 show that the vehicle-treated Tg2576 mice exhibited nearly a 
1.7-fold increase in AchE activity and a 0.6-fold decrease in Chat activity compared to WT. 
The AchE activity of mice treated with the middle and high doses of liquiritigenin decreased 
markedly to 88.0±7.9% and 67.9±5.9% respectively compared with that of the vehicle-treated 
Tg2576 mice. Chat activity in these mice increased to 119.0±12.7% (middle dose) and 
150.9±11.2% (high dose) compared with the vehicle-treated mice.  
3.4 Liquiritigenin inhibited the expression of Aβ/A4 in different brain regions 
Aǃ/A4 load was quantified in the hippocampus CA1, subiculum, cortex and amygdala. 
Fig. 3(A) shows representative images of Aǃ/A4 immunostaining in the brain. Not all the 
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liquiritigenin-treatment groups are shown due to limitations of space. According to a 
report by Carroll (Carroll et al., 2007), amyloid A4 exhibits a different staining pattern to 
that of Aǃ; amyloid A4 localises to the periphery of the cell body, while Aǃ deposits 
localised throughout the cell body, often with a punctuate distribution. The localisation of 
Aǃ/A4 is shown in Fig. 3(A), and some dense extracellular accumulation of Aǃ could also 
be seen, especially in the cortex. However, because it is difficult to distinguish between 
different types of immunoreactive cells when doing quantitative analysis, we counted all 
positive staining in. For the quantitative analysis of immunostaining, the Aǃ/A4 load of 
the vehicle-treated Tg2576 mice was set as 100%. We found that the vehicle-treated 
Tg2576 mice had a higher Aǃ/A4 load in the hippocampus CA1, subiculum, cortex and 
amygdala, as compared with the WT mice. Liquiritigenin treatment attenuated the 
increase in the Aǃ/A4 load to some extent. The Aǃ/A4 load in the hippocampus was 
93.3±14.6% (low dose), 65.3±7.1% (medium dose) and 55.1±9.0% (high dose) of that 
observed in the vehicle-treated Tg2576 mice; in the cortex, the load decreased to 
91.4±13.2%, 72.1±9.1% and 67.2±7.5%, and in the amygdala, the load decreased to 
87.6±8.7%, 66.9±6.1% and 53.7±5.7%, as shown in Fig. 3(B). The Aǃ/A4 in the subiculum 
was not markedly changed by liquiritigenin treatment. 
 
 
 
 
Fig. 2. Effects of liquiritigenin on the performance of Tg2576 mice in the Morris water maze 
task and shuttle box task.  (A) Escape latency with reference to the memory task in the 
Morris water maze test. (B) The time required to reach the previous platform location in the 
Morris water maze test probe task. (C) Time spent in the platform quadrant in the Morris 
water maze test probe task. (D) Shocks received during training in the shuttle box task. (E) 
Length of shocks received in the shuttle box task. (F) Initiative escaping time in shuttle box 
task. Morris water maze tasks were given on days 91-95 and shuttle box tasks were given on 
days 98-102, following the administration of liquiritigenin. The values shown are 
mean±SEM for 10 animals. # p<0.05 vs. WT, * p<0.05 vs. vehicle-treated Tg2576 mice 
(Dunnett’s test).  
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Group Dose (mg/kg/d) AchE (%) Chat (%) 
WT - 61.4±6.2 171.4±14.2 
Vehicle - 100.0±8.5# 100.0±11.7# 
liquiritigenin 3 102.0±10.2 105.8±13.1 
 10 88.0±7.9* 119.0±12.7* 
 30 67.9±5.9* 150.9±11.2* 
Table 1. Effect of liquiritigenin on brain AchE and Chat activity in Tg2576 mice (mean±SEM, 
n=10/group). Acetylcholinesterase (AchE) and choline acetyltransferase (Chat) activity. The 
activities in the vehicle-treated Tg2576 mice were defined as 100%. # p<0.05 vs. WT, * p<0.05 
vs. vehicle-treated Tg2576 mice (Dunnett’s test). 
3.5 Liquiritigenin treatment alters the protein levels of Aβ but not amyloid A4 
Aǃ/A4 levels were further detected by Western blotting. As shown in Fig. 4(A), the two 
bands near 100 kDa are amyloid A4 and the band near 40 kDa is oligomeric form of Aǃ, 
according to the manufacturer. The protein level was calculated as a ratio against the 
loading control ǃ-tubulin. As shown in Fig. 4(B), the vehicle-treated Tg2576 mice exhibited a 
higher level of both amyloid A4 (2.14-fold increase) and Aǃ (2.8-fold increase) load 
compared with the WT mice. There was no difference in amyloid A4 load between the 
liquiritigenin-treated groups and the vehicle-treated Tg2576 group. However, the oligomeric 
form of Aǃ protein levels were significantly lower in mice treated with the middle and high 
doses of liquiritigenin, decreasing to 0.71- and 0.57-fold of the level in the vehicle-treated 
Tg2576 mice, respectively. 
3.6 Liquiritigenin treatment promotes an increase in neuronal cell number 
Neuronal cell loss was examined by nissl staining with cresyl violet. Fig. 5(A) is a 
representative image of nissl staining, which shows that the vehicle-treated Tg2576 mice 
exhibited a loss of neurons in the hippocampus CA1 and cortex, and that liquiritigenin 
treatment attenuated this loss to a degree. Quantitative analysis in Fig. 5(C) shows that the 
number of neurons in the vehicle-treated Tg2576 mice decreased to 54.5±8.5% of WT mice in 
the hippocampus and 63.2±9.2% in the cortex. Liquiritigenin treatment markedly increased 
the neuron numbers compared with the vehicle-treated Tg2576 mice: in the 10 mg/kg/d 
dosing group, the number of neurons increased to 122.5±14.7% in the hippocampus and 
117.5±15.0% in the cortex while, in the 30 mg/kg/d dosing group, the numbers increased to 
163.8±17.7% in the hippocampus and 134.1±15.0% in the cortex.  
3.7 Liquiritigenin treatment attenuates astrocytosis 
In AD, deposition of Aǃ in senile plaques is associated with astrocytic proliferation. Thus, 
we investigated whether liquiritigenin would decrease astrogliosis. Astrocytes were 
identified by GFAP immunoreactivity. We quantified the GFAP load specifically in the 
hippocampus CA1 due to the importance of this region in memory, and we have found in 
this study that astrocytosis was apparent in CA1. Fig. 5(B) shows representative images of 
GFAP immunohistochemistry in CA1. Quantitative analysis of CA1 subfields in Fig. 5(D) 
shows that the vehicle-treated Tg2576 mice had a 2.43-fold increase in GFAP load compared 
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with the WT mice, and that GFAP load was decreased significantly in mice subjected to 
middle and high doses of liquiritigenin compared to the vehicle-treated Tg2576 mice (10 
mg/kg/d: 85.5±9.0%, 30 mg/kg/d: 73.8±7.6%).  
 
 
Fig. 3. Liquiritigenin attenuated Aǃ/A4 accumulation in different brain regions. (A) 
Representative images of Aǃ/A4 immunohistochemistry of different brain regions. Scare 
bar: 50 μm. (B) Quantification of Aǃ/A4 load. The level of Aǃ/A4 immunoreactivity was 
quantified in the hippocampus CA1, subiculum, amygdala and cortex, by Motic Images 
Advanced 3.2 software. The average Aǃ/A4 load of the vehicle-treated Tg2576 mice was 
defined as 100%. The values shown are mean±SEM for 10 animals. # p<0.05 vs. WT, * p<0.05 
vs. vehicle-treated Tg2576 mice (Dunnett’s test). 
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Fig. 4. The effect of liquiritigenin on Aǃ/A4 accumulation, assayed by Western blotting.  
(A) Representative Western blots. The two bands near 100 kDa are amyloid A4 and the 
single band near 40 kDa is oligomeric form of Aǃ. (B) Quantification of Western blotting. 
The optical density of Aǃ bands was quantified with Scion Image software. ♀ indicates 
female and ♂ indicates male. The values shown are mean±SEM for 10 animals. # p<0.05 vs. 
WT, * p<0.05 vs. vehicle-treated Tg2576 mice (Dunnett’s test). 
3.8 Liquiritigenin decreased the expression of Notch-2 in vivo and in vitro 
Notch signalling is involved in many critical cellular processes, such as neurogenesis, 
proliferation and apoptosis etc. The preliminary experiment results of a microarray assay 
performed in our lab suggested that liquiritigenin had a potential inhibitory activity on 
Notch-2 mRNA (down-regulated for 5.34 times) and protein expression (down-regulated for 
3.12 times) in normal rat hippocampal neurons (unpublished data). Thus, we investigated 
whether liquiritigenin had a similar inhibitory effect on Notch-2 in vivo and in vitro. As 
shown in Fig. 6(A), Notch-2IC (the active fragment) appears as a band near 100 kDa. Fig. 6(B) 
shows that the vehicle-treated Tg2576 mice expressed a 1.73-fold higher level of Notch-2IC 
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than WT mice. The treatment of Tg2576 mice with liquiritigenin resulted in a mild but 
significant decrease (10 mg/kg/d: 18.4%; 30 mg/kg/d: 23.7%) in Notch-2IC expression 
compared with vehicle-treated ones, while the dose of 3 mg/kg/d liquiritigenin did not 
seem to influence Notch-2 levels.  
 
 
Fig. 5. Liquiritigenin attenuated neuron loss and excess proliferation of astrocytes in the 
brains of Tg2576 mice.  (A) Representative image of nissl staining. (B) Representative image 
of GFAP immunostaining. (C) Quantification of nissl staining. (D) Quantification of GFAP 
load. Quantification was performed with Motic Images Advanced 3.2 software. The values 
shown are mean±SEM for 10 animals. # p<0.05 vs. WT, * p<0.05 vs. vehicle-treated Tg2576 
mice (Dunnett’s test). 
In vitro studies showed similar results. The treatment of primary neurons obtained from 
newborn C57 mice with 0.2 μM or 2 μM liquiritigenin resulted in a 37.1% to 48.6% reduction in 
Notch-2IC as assayed by Western blotting. The introduction of the ER inhibitor ICI 182 780 
blocked the effects of liquiritigenin, as shown in Fig. 6(C). RT-PCR showed that the treatment 
of primary neurons with 0.2 or 2 μM liquiritigenin decreased levels of Notch-2 mRNA by 30%-
60% compared with the control. Treatment with ICI 182 780 blocked the effect of liquiritigenin 
completely, but had no independent effect on Notch-2 expression, as shown in Fig. 6(D).  
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Fig. 6. Liquiritigenin inhibited Notch-2 expression both in vivo and in vitro.  
(A) Representative Western blots from tissue samples. (B) Quantification of Western blots. 
(C) Effect of liquiritigenin on Notch-2 protein expression in vitro shown by Western 
blotting. (D) Effect of liquiritigenin on Notch-2 mRNA expression in vitro shown by RT-
PCR. Band densities were quantified with Scion Image software. The values shown are 
mean±SEM. # p<0.05 vs. WT or control, * p<0.05 vs. vehicle-treated Tg2576 mice, p<0.05 
vs. liquiritigenin (0.2 μM)-treated cells (Dunnett’s test). 
3.9 Liquiritigenin inhibits amyloidosis in vitro  
To explore the mechanisms underlying the liquiritigenin-mediated improvement in AD-
type cognitive function and Aǃ neuropathology, we investigated whether liquiritigenin 
influenced Aǃ peptide oligomerisation in vitro. Aǃ is a 39-43 amino acid peptide that 
derives from APP. Aǃ1-42 is the most easily amyloidogenic form, so it was used in the present 
study. Liquiritigenin was added to soluble Aǃ1-42 and these tubes were stored at 37 for 7d to 
allow fibril formation. The thioflavin-T assay shown in Fig. 7(A) revealed that the 
fluorescence of Aǃ1-42 incubated with 0.2, 2 and 20 μM liquiritigenin was decreased to 
96.9±2.5%, 77.2±7.0% and 72.5±6.4% of the fluorescence observed for Aǃ1-42 incubated alone. 
Treatment with melatonin caused the fluorescence to decrease to 49.9%.  
Primary cerebral neurons obtained from newborn C57 mice were treated with the 
conditioned Aǃ1-42 for 72 h. Cell viability was measured by 3-[4,5-dimethyl-thiazolyl]-2,5- 
diphenyl-2- tetrazolium bromid assay and LDH release. As shown in Fig. 7(B), incubation 
with Aǃ1-42 reduced cell viability to 69.5±3.8% (P<0.05 vs. control) while neurons incubated 
with melatonin-treated Aǃ1-42 were 85.4±2.4% viable (P<0.05 vs. Aǃ25-35). When the Aǃ1-42 
were treated with 0.2, 2 or 20 μM liquiritigenin, the cell viability was increased to 71.4±5.8 % 
(P>0.05 vs. Aǃ25-35), 78.0±4.7% (P<0.05 vs. Aǃ25-35) and 82.2±3.7% (P<0.05 vs. Aǃ25-35), 
respectively. These results showed that Aǃ1-42 alone caused a 4.3-fold increase in LDH 
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leakage compared to controls (P<0.05 vs. control), and that LDH leakage in 0.2 and 2 μM 
liquiritigenin-treated groups decreased to 80.3±4.2% and 70.1±4.8% that of Aǃ1-42 alone, 
respectively (P<0.05 vs. Aǃ25-35). Treatment with 0.2 μM liquiritigenin did not affect LDH 
leakage, as shown in Fig. 7(C). 
 
 
Fig. 7. Liquiritigenin inhibited Aǃ1-42 fibril formation in vitro.  Soluble Aǃ1-42 (100 μM) was 
incubated with liquiritigenin (0, 0.02, 0.2 and 2 μM) or 100 μM melatonin (positive control) 
at 37°C for 7 d so as to induce fibril formation. (A) The inhibitory effects of liquiritigenin on 
fibril formation were measured by thioflavin-T. The fluorescence intensity indicates fibril 
formation. (B) Cell viability and (C) LDH release were detected in primary neurons treated 
with the conditioned Aǃ1-42 for 72 h. Values shown are mean±SEM. # p<0.05 vs. control, * 
p<0.05 vs. Aǃ1-42-treated alone (Dunnett’s test). 
4. Discussion 
A primary clinical concern regarding hormone replacement therapy in postmenopausal 
women is the increased risk of breast and uterine cancer associated with prolonged 
treatment with estrogenic compounds. However, hormone replacement therapy is also 
reported to be associated with a reduced incidence and severity of AD. Therefore, the 
development of neuro-selective estrogen receptor agonists that exert beneficial effects on the 
brain but minimal effects on other estrogen-responsive tissues is of critical importance. In the 
present study, we investigated the efficacy of the newly found selective estrogen receptor 
agonist liquiritigenin in regulating neuropathology in the Tg2576 mouse model of AD. We 
observed that liquiritigenin treatment significantly improved behavioural performance in such 
mice. At the molecular level, liquiritigenin treatment reduced Aǃ accumulation in some brain 
regions, regulated the function of the acetylcholine system, increased the average neuron 
number in the brain, and attenuated astrogliosis in the hippocampus. More interestingly, we 
have found that liquiritigenin can inhibit Notch-2 expression in an ER-dependent way. 
Previously, work from Carroll has shown that administration of propylpyrazole triol (an ERǂ 
agonist) but not diarylpropionitrile (an ERǃ agonist) can improve behavioural performance of 
3×Tg-AD model mice, and that both propylpyrazole triol and diarylpropionitrile can reduce 
Aǃ accumulation in the brain (Carroll and Pike, 2008). Our results are not inconsistent with 
these observations, and it may that, although liquiritigenin has been reported as a ERǃ agonist, 
it also has been shown to exhibit some affinity to ERǂ (Hillerns et al., 2005) – a report that we 
are agree with, based on the results of a reporter gene-based cell screening method for ER 
subtype ligands in our lab (unpublished data). Besides, the difference in behavioural assays 
used in these studies might also cause some discrepancies in results.  
Since the Morris water maze and shuttle box tests investigate distinct motivations, and 
different skills are required for a good performance in each task, we used both of these tests 
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to examine the memory skills of the mice in this study. In the Morris water maze test, the 
mice in all three liquiritigenin dosing groups exhibited a better performance in the reference 
memory task. The middle and high dosing groups also needed less time to reach their 
destination in the probe task, but only mice receiving the 30 mg/kg/d dose of liquiritigenin 
treatment showed improvement in the time spent in the quadrant where the platform had 
been located. In the shuttle box test, the mice that received the middle and high dosages of 
liquiritigenin performed better than the vehicle-treated mice, indicating that a 3 mg/kg/d 
dose may be too low to be effective in this test. Furthermore, a dose higher than 30 
mg/kg/d is likely to be unnecessary as higher doses did not cause further improvement in 
other AD models that we used previously (unpublished observations).  
The cholinergic system plays a crucial role in cognitive functions, and most AD patients 
exhibit a reduction in cholinergic functioning. Estrogen treatment has been found to directly 
enhance the activity of the cholinergic system by some researchers (Kompoliti et al., 2004; 
Bora et al., 2005). In the present study, we found that the selective ERǃ agonist liquiritigenin 
enhanced the activity of Chat and decreased AchE activity, thus enhancing cholinergic 
functioning. Given that liquiritigenin is a kind of phytoestrogen, our observations are 
consistent with other research showing that phytoestrogens, such as soy isoflavones, can 
reverse the increase of AchE observed in ovariectomised rats (Monteiro et al., 2007). The 
effects of liquiritigenin on the cholinergic system may be related to its activity on ER, and 
further research will be required to verify this hypothesis.  
Excessive deposition of Aǃ in the brain is a key characteristic of AD patients. In APP Tg 
mice, Aǃ deposits appears in a few months after birth and they progressively accumulate 
(Reilly et al., 2003). We chose to use 10-month old mice in this study because serious Aǃ 
accumulation has already occurred within this population, and we wanted to observe the 
therapeutic effects of treatment with liquiritigenin, rather than any preventive effects. In this 
study, we used both immunohistochemistry and Western blotting to measure Aǃ 
accumulation. The antibody that we used cross-reacted with amyloid A4 and oligomeric 
form of Aǃ (toxic fragment), both of which are given rise to from APP, and they could both 
be clearly and easily discriminated in Western blots, while immunohistochemistry with this 
antibody could effectively detect Aǃ /A4 load in different regions of brain. Accordingly, the 
two methods were used. We report in the present study that liquiritigenin treatment 
attenuates Aǃ /A4 load in the hippocampus, cortex and amygdala, but not in the 
subiculum. This conclusion is consistent with what is known about ER distribution in the 
brain. Studies in both humans and rodents have demonstrated a differential distribution of 
ERǂ and ERǃ in brain regions affected in AD, including the hippocampus, frontal cortex and 
the amygdala. In situ hybridisation studies have demonstrated a higher density of ERǃ-
expressing cells compared with ERǂ-expressing cells in the hippocampus (Mehra et al., 
2005) and layers 4-6 of the cortex (Shughrue et al., 1997 ; Mitra et al., 2003 ), but similarly 
high levels of ERǃ- and ERǂ- expressing cells were expressed in the amygdala (Shughrue et 
al., 1997 ). A recent study showed that ERǃ in the hippocampus and/or cortex is required 
for enhanced performance in cognitive tasks and anti-anxiety behaviour in mice (Walf et al., 
2009). Our results are also consistent with the hippocampus-dependent nature of the 
behavioural tasks. Further complicating this issue, the mechanisms by which estradiol or 
selective estrogen receptor agonists propylpyrazole triol, diarylpropionitrile and 
liquiritigenin reduce levels of Aǃ have not been clearly elucidated. Here, we have shown 
that liquiritigenin can inhibit amyloidosis in a cell-free system in vitro, so it is possible that 
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the regulation of Aǃ involves non-genomic cell signalling besides classic genomic pathways 
(Zhang et al., 2004), potentially involving the molecular structure of liquiritigenin itself. It is 
worth noting that liquiritigenin doesn’t have a significant effect on amyloid A4, which is 
another form of APP, and it may indicate that liquiritigenin can regulate the abnormal 
cleavage of APP, to some extent, but that it does not influence the expression level of APP. 
Clearly, the underlying mechanisms of liquiritigenin should be explored further. 
Nissl staining was used to assess whether liquiritigenin could attenuate the neuronal cell 
death observed in APP transgenic mice. We hypothesise that the positive results of this 
assay may be due to liquiritigenin treatment triggering neurogenesis, as we have previously 
observed that liquiritigenin can induce the differentiation of primary stem cells into neurons 
through the pathway of Notch in vitro (Liu et al., 2010b). Consistent with this, liquiritigenin 
inhibits Notch-2 expression both in vivo and in vitro in the present study. It has been shown 
that Notch signal activation can inhibit neuronal differentiation, whereas a glial progenitor 
derived from a stem cell differentiates into an astrocyte with the help of Notch signals 
(Louvi et al., 2006). Therefore, it is possible that when neurons are damaged, the Notch 
signal pathway may be inhibited with the help of liquiritigenin, and as a result, more 
endogenous stem cells in the brain may develop into neurons. Our finding that Notch-2 is 
increased in Tg2576 mice is supported by other researchers’ observations that Notch-2 is 
upregulated in aged and cognitively impaired rats (Bowe et al., 2007), which indicates that 
elevated Notch-2 signalling may correlate with memory disorders and aging.  
Recent research indicates that estradiol inhibited Notch activity in ERǂ-positive breast 
cancer cells, and the ER inhibitors tamoxifen and raloxifene, can block this effect by 
reactivating Notch, suggesting a model in which estrogen inhibits Notch via ERǂ (Rizzo et 
al., 2008). In the present paper, we propose that liquiritigenin may exert its inhibitory effect 
on Notch-2 through ERǃ because liquiritigenin has a much higher transcriptional activation 
activity on ERǃ than on ERǂ. However, as ICI 182 780 is an ER blocker on both ERǂ and 
ERǃ, it is impossible to distinguish between these two possibilities in our culture system. We 
have begun to test our hypothesis with ERǃ knockdowns, which are ongoing at the time of 
writing. In any case, we consider that this triggering of neurogenesis is of great importance, 
and may work as a universal, endogenous protective mechanism against neuronal insults in 
a damaged brain, because the newly generated neurons are not subject to immune rejection 
and may have a good chance of integration into the original neural circuits.  
As an exploration of the possibility of AD treatment with selective estrogen receptor 
agonists, the present report shows that the ERǃ agonist liquiritigenin has a promising 
future. Our data confirms the potential of selective estrogen receptor agonists, especially 
Neuro-selective estrogen receptor agonists, in protecting against AD neuropathology, and it 
supports continued development and investigation in this field. Interestingly, we found that 
liquiritigenin has effects on both male and female mice. This may be due to the fact that ERǃ 
is less correlated with sex than is ERǂ (Shughrue et al., 1997 ; Gustafsson, 2003). However, 
more research is needed to confirm the effects of liquiritigenin. From a mechanistic 
standpoint, there is a significant need for targeted research in order to better elucidate the 
signalling involved in both estradiol and selective estrogen receptor agonists mediated 
activation of genomic and non-genomic kinase signalling pathways. Relative studies has 
shown recently that estradiol could work through any of several ERs, including the novel G-
protein coupled receptor GPR30, to enhance the learning and memory ability in 
ovariectomised rats (Hammond et al., 2009). As such, and subsequently, in our gonadally 
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intact models, animals could be simultaneous treated with an antagonist of ER and 
examined as to whether the effects of liquiritigenin would be antagonised. Nevertheless, the 
following research should move this interesting field forward, and aim at answers to many 
of the key questions that remain.  
5. Conclusion 
In summary, as a newly found selective ERǃ agonist, liquiritigenin could improve the 
behavioural performance of Tg mice and attenuated Aǃ accumulation pathologies both in 
vivo and in vitro. The effects of liquiritigenin may be due to its inhibition of neuron loss and 
astrocytosis in the brain, which could be through the Notch signalling pathway. These 
findings provide evidence for the beneficial activities of the selective estrogen receptor 
agonist liquiritigenin in a mouse model of AD and support the continued investigation of 
selective estrogen receptor agonists as an alternative to estrogen-based treatment in 
reducing the risk of AD.  
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